Drug Trial Radar · NCT05050084
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,050
Planned (sponsor's estimate)
Start
Dec 6, 2021
Primary completion
Nov 11, 2026
Study completion Nov 11, 2031
Sponsor
- Lead sponsor
- NRG OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Sep 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
Conditions
- Prostate Adenocarcinoma
Interventions
BicalutamideDrug
Drug
BuserelinDrug
Drug
DarolutamideDrug
Given PO
DegarelixDrug
Drug
FlutamideDrug
Drug
GoserelinDrug
Drug
HistrelinDrug
Drug
LeuprolideDrug
Drug
Radiation TherapyRadiation
Undergo RT
RelugolixDrug
Drug
TriptorelinDrug
Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Distant metastasis (DM) (De-intensification study)Time frame: From randomization to the detection of distant metastasis by conventional imaging, assessed up to 5 years
- Metastasis-free survival (MFS) (Intensification study)Time frame: From randomization until the occurrence of distant metastasis by conventional imaging or death from any cause, assessed up to 5 years
Locations
576 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Banner MD Anderson Cancer Center
Gilbert, Arizona
Arizona Center for Cancer Care - Gilbert
Gilbert, Arizona
Arizona Center for Cancer Care-Peoria
Peoria, Arizona
Arizona Center for Cancer Care - Phoenix
Phoenix, Arizona
Arizona Center for Cancer Care - Scottsdale
Scottsdale, Arizona
Arizona Center for Cancer Care-Surprise
Surprise, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California
Tower Cancer Research Foundation
Beverly Hills, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
City of Hope Corona
Corona, California
City of Hope Comprehensive Cancer Center
Duarte, California
Kaiser Permanente Dublin
Dublin, California
UC San Diego Health System - Encinitas
Encinitas, California
Kaiser Permanente-Fremont
Fremont, California
Washington Hospital
Fremont, California
Kaiser Permanente Fresno Orchard Plaza
Fresno, California
Kaiser Permanente-Fresno
Fresno, California
Marin General Hospital
Greenbrae, California
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California
City of Hope at Irvine Lennar
Irvine, California
UC San Diego Moores Cancer Center
La Jolla, California
City of Hope Antelope Valley
Lancaster, California
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Fremont - Rideout Cancer Center
Marysville, California
Memorial Medical Center
Modesto, California
Kaiser Permanente- Modesto MOB II
Modesto, California
Kaiser Permanente-Modesto
Modesto, California
Providence Queen of The Valley
Napa, California
Kaiser Permanente-Oakland
Oakland, California
Saint Joseph Hospital - Orange
Orange, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Kaiser Permanente-Roseville
Roseville, California
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California
Kaiser Permanente Downtown Commons
Sacramento, California
Showing 40 of 576 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.